leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 22:06:25 - browse：77

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

explore

WSS

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Medicare must police algorithms in Medicare Advantage, Dems say

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Key Senate panel to consider PBM, drug pricing reform package

Supreme Court to hear if Covid misinformation is protected speech

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

knowledge

leisure time

hotspot

Moonlake's readout produced a cash windfall. Risks remain

WuXi Biologics execs register to lobby as Congress comes for the company

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Activists slam private health insurers over coverage restrictions

How to convince healthy people to buy insurance

Anesthesiologist group: stop taking Ozempic before surgery

Infant mortality in U.S. rose last year for first time in decades: CDC

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: ESMO highlights & Roivant's big deal

focus

Free medical tuition alone isn't enough to close gaps in primary care

Kidney transplant patients stopped immunosuppressants in trial

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Free medical tuition alone isn't enough to close gaps in primary care

Live blog: Hearing on CRISPR

Novo Nordisk testing Wegovy against alcohol

Wikipedia

explore

focus

focus